Therapeutic targeting of FASN (e.g., Cerulenin, siFASN, miR-195, miR-424) reduces proliferation, metastasis, and invasion in various cancers. Combinatorial strategies improve outcomes by inhibiting Rb/AMPK signaling or reducing autophagy. Here, RB1 is linked to cancer.